146 related articles for article (PubMed ID: 34118322)
1. Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
Fortuny Bauzá M; Cañete Pizarro F; Calm Salvans A; Calafat Sard M; Domènech Morral E
Gastroenterol Hepatol; 2022 Apr; 45 Suppl 1():11-12. PubMed ID: 34118322
[No Abstract] [Full Text] [Related]
2. Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.
Gilmore R; Hilley P; Srinivasan A; Choy M; De Cruz P
J Crohns Colitis; 2022 Jan; 16(1):166-168. PubMed ID: 34159363
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Shaffer SR; Huang E; Patel S; Rubin DT
Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
Kotwani P; Terdiman J; Lewin S
J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
[TBL] [Abstract][Full Text] [Related]
6. Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis.
Yang Q; Chen L; Feng L; Liu C; Fang L; Liu Z; Sun X
Inflamm Bowel Dis; 2021 Nov; 27(12):e157-e158. PubMed ID: 34398196
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
[No Abstract] [Full Text] [Related]
8. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
Gregory MH; Ciorba MA; Deepak P; Christophi GP
Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
[No Abstract] [Full Text] [Related]
9. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
10. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
[TBL] [Abstract][Full Text] [Related]
11. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF.
Sedano R; Jairath V
Inflamm Bowel Dis; 2021 Apr; 27(5):e59-e60. PubMed ID: 33484120
[No Abstract] [Full Text] [Related]
13. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.
Choy MC; Seah D; Faleck DM; Shah SC; Chao CY; An YK; Radford-Smith G; Bessissow T; Dubinsky MC; Ford AC; Churilov L; Yeomans ND; De Cruz PP
Inflamm Bowel Dis; 2019 Jun; 25(7):1169-1186. PubMed ID: 30605549
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Dulai PS; Singh S; Jairath V; Ma C; Narula N; Vande Casteele N; Peyrin-Biroulet L; Vermeire S; D'Haens G; Feagan BG; Sandborn WJ
Aliment Pharmacol Ther; 2020 Feb; 51(4):435-445. PubMed ID: 31755121
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience.
Honap S; Pavlidis P; Ray S; Sharma E; Anderson S; Sanderson JD; Mawdsley J; Samaan MA; Irving PM
Inflamm Bowel Dis; 2020 Oct; 26(11):e147-e149. PubMed ID: 32566937
[No Abstract] [Full Text] [Related]
16. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
17. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
[TBL] [Abstract][Full Text] [Related]
18. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis.
Dai C; Jiang M; Huang YH
J Gastroenterol Hepatol; 2021 Jul; 36(7):2024-2025. PubMed ID: 33880817
[No Abstract] [Full Text] [Related]
19. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
20. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
